CYP19A1 and Hypercholesterolemia: An analysis of pooled data from seven clinical trials (N = 30,023 patients) demonstrated that longer duration of aromatase inhibitor use was associated with a statistically significant increase in the odds of hypercholesterolemia as compared with tamoxifen31.